ADVA
18.2.2020 09:02:11 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched the industry’s most compact demarcation and aggregation technology, bringing cost-effective MEF 3.0-certified 100Gbit/s services to the network edge. The ADVA FSP 150-XG400 Series enables businesses and mobile network operators (MNOs) to easily scale their metro networks and tackle booming bandwidth demand. Specifically engineered to deliver MEF 3.0 Carrier Ethernet 100Gbit/s demarcation and 10Gbit/s service aggregation, the new product family features the market’s only uncompromised line-rate 100Gbit/s activation testing. It also supports hardware-based timing for ultra-precise frequency and phase synchronization, making it the ideal choice for radio access networks. With its high-density and environmentally hardened design, the ADVA FSP 150-XG400 Series is also easy to deploy in space-restrictive locations with no temperature control – a key requirement for the rollout of 5G connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200218005165/en/
“The arrival of 5G is bringing unprecedented data speeds, but mobile applications can only be as fast as the backhaul network. That’s why MNOs are now looking to upgrade their access infrastructure from 10Gbit/s to 100Gbit/s line rates. Our FSP 150-XG400 Series supports a smooth and extremely cost-effective migration to higher capacity while also enabling the distribution of precise network synchronization that next-generation services require,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “With their compact, ETSI-compliant design, our FSP 150-XG400 devices remove the need for deep shelves and excessive rack height units. This makes it easy and affordable to seamlessly upgrade from 1Gbit/s to 10Gbit/s or even 100Gbit/s service delivery. What’s more, the new solutions feature integrated testing capabilities, so operators don’t have to bother with expensive high-bitrate testing equipment.”
The ADVA FSP 150-XG400 Series of high-density service aggregation solutions is the ultimate tool for scaling edge networks for future wholesale, business, mobile fronthaul and backhaul service needs. Available in a 1RU or 2RU form factor, the unprecedentedly compact and highly versatile product range features 1, 10, 25, 40 or 100GbE interfaces. Each device comes with carrier-class Ethernet OAM and Y.1564 feature sets, including unique full line-speed activation testing for services up to 100Gbit/s. The ADVA FSP 150-XG400 Series supports network overlay capabilities for the delivery of MEF services over IP networks. It also provides standard SDN interfaces and can be directly controlled from open source and commercial SDN controllers. Able to withstand an extended temperature range, the ADVA FSP 150-XG400 Series avoids the high cost of air conditioning, enabling ease of deployment even in extreme environments.
“Our newest product family removes all the roadblocks and makes the task of transforming metro networks simple. With our FSP 150-XG400 Series delivering high-density demarcation and aggregation, businesses can expand and embrace the potential of IoT, and operators can deliver the next level of resilient SLA-based Carrier Ethernet services,” commented James Buchanan, GM, Edge Cloud, ADVA. “No other solution available offers such high port count, full testing capabilities and comprehensive network synchronization features with this level of design density. Our devices also provide proven OAM capabilities as well as fully automated service activation. Whether you need high-speed connectivity for cloud-centric business applications or building your enterprise IoT architecture, our FSP 150-XG400 Series has you covered.”
Watch this video for more information on the FSP 150-XG400 Series: https://youtu.be/bCzD9ffS0N8 .
Further details are also available in these slides: https://adva.li/fsp-150-xg400-series-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005165/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
